Astellas Gene Therapies

Overview

Astellas Gene Therapies (Astellas Gene) formerly known as Audentes Therapeutics Inc is a biotechnology company. It focuses on the development and commercialization of gene therapy products for rare diseases. The company’s pipeline products include AT132, intended for the treatment of X-linked myotubular myopathy; AT982, for the treatment of Pompe disease; AT342, for the treatment of crigler-najjar syndrome; and AT307, for the treatment of CASQ2-related catecholaminergic polymorphic ventricular tachycardia. Astellas Gene offers viral vectors for gene therapy most frequently and track record off adeno-associated virus vector (AAV) in non-pathogenic product, among others. The company has collaboration with various patient, research and medical communities to advance its product candidates. Astellas Gene is headquartered in San Francisco, California, the US.
Key Stats
Address
17th Floor, 600 California Street, San Francisco, California
Headquarters

United States of America

Contact

1 415 6386556

Industry

Pharmaceuticals and Healthcare

Peer Comparison

Key Parameters Astellas Gene TherapiesAmicus Therapeutics IncNektar TherapeuticsDimension Therapeutics Inc
Key Information
Headquarters United States of America United States of America United States of America United States of America
Headquarter City San Francisco PHILADELPHIA SAN FRANCISCO Cambridge
Headquarter State/Province California Pennsylvania California Massachusetts
No. of Employees - 483 718 -
Entity Type Private Public Public Private

Products & Services

Astellas Gene operates as a biotechnology company. The key products under development offered by the company include the following:

Products
  • AT132 - X-linked Myotubular Myopathy
  • AT342 - Crigler-Najjar Syndrome
  • AT307 - Related Catecholaminergic Polymorphic Ventricular Tachycardia
  • Vitae Eget Libero

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2019 Corporate Changes/Expansions In April, Audentes Therapeutics to launch an advanced internal cGMP plasmid manufacturing facility in South…
2019 Contracts/Agreements In December, the company agreed to be acquired by Astellas Pharma Inc.
2017 Regulatory Approval In February, the company's investigational new drug application for AT342, which is used in the…
2016 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2016 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2015 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Cardiogen Sciences, Inc.
Audentes Therapeutics UK Ltd

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
02 Dec 2019 Astellas Pharma Acquires Audentes Therapeutics Acquisition Astellas Pharma Inc Astellas Gene Therapies
08 Apr 2019 Audentes Therapeutics Enters into Licensing Agreement with Nationwide Children's Hospital Licensing Agreement Astellas Gene Therapies Nationwide Children's Hospital
10 Oct 2018 Audentes Therapeutics Prices Public Offering of Shares for USD150.8 Million Equity Offering Astellas Gene Therapies
23 Jan 2018 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
08 Aug 2017 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
10 Apr 2017 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit